Clofoctol and sorafenib inhibit prostate cancer growth via synergistic induction of endoplasmic reticulum stress and UPR pathways

Clofoctol and sorafenib inhibit prostate cancer growth via synergistic induction of endoplasmic reticulum stress and UPR pathways

Lixia Fan,1,* Zhenglei He,1,* Sarah A Head,2 Yinghui Zhou,1 Ting Lu,1 Xulong Feng,1 Xueqing Zhang,1 Meng Zhang,1 Yongjun Dang,3 Xinghong Jiang,4 Minghua Wang1 1Department of Biochemistry and Molecular Biology, Medical College, Soochow University, Suzhou, Jiangsu, China; 2Department of Pharmacology a...

Full description

Bibliographic Details
Main Authors: Fan L, He Z, Head SA, Zhou Y, Lu T, Feng X, Zhang X, Zhang M, Dang Y, Jiang X, Wang M
Format: Article
Language:English
Published: Dove Medical Press 2018-10-01
Series:Cancer Management and Research
Subjects:
drug combination therapy
prostate cancer
clofoctol
sorafenib
Online Access:https://www.dovepress.com/clofoctol-and-sorafenib-inhibit-prostate-cancer-growth-via-synergistic-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/clofoctol-and-sorafenib-inhibit-prostate-cancer-growth-via-synergistic-peer-reviewed-article-CMAR

Similar Items